BRISBANE, May 29, 2019 (GLOBE NEWSWIRE via COMTEX) -- CareDx, Inc. (NAS:CDNA) , a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will showcase 12 abstracts and host a dynamic lunch symposium during the American Transplant Congress June 1- 5, 2019 in Boston, MA.
CareDx will formally announce KidneyCare during a lunch symposium alongside transplant key opinion leaders on Tuesday, June 4th. KidneyCare combines clinically validated AlloSure testing with AlloMap Kidney and iBox to deliver personalized and prognostic solutions for transplant patients.
"Building on the momentum of AlloSure, there is incredible potential for KidneyCare to enable us to tailor treatment for kidney transplant patients. The value is not only to identify when there may be an issue, but to reduce immunosuppression in a subset of patients," said Ram Peddi, MD, Transplant Nephrologist at California Pacific Medical Center. "We are excited to bring personalized medicine to transplantation with KidneyCare."
Seven leaders in transplantation will speak during the CareDx Lunch Symposium titled Better Transplant Outcomes Start with Better Transplant Surveillance, on June 3at 1pm EST in the Grand Ballroom of the Sheraton Hotel in Boston:
-- Matthew Weir, MD, University of Maryland
-- Alexandre Loupy, MD, PhD, Paris Transplant Group
-- Vikas Dharnidharka, MD, MPH, Washington University
-- Daniel C. Brennan, MD, FACP, Johns Hopkins Hospital
-- Stanley C. Jordan, MD, FASN, FAST, Cedars-Sinai Transplant Center
-- Tarek Alhamad, MD, MS, FACP, FASN, Barnes Jewish Hospital, Washington
-- Anthony Langone, MD, FAST, Vanderbilt University Medical Center
CareDx will host a press conference following the lunch symposium at 4pm in the Sheraton Hotel with Anthony Langone, MD and Alexandre Loupy, MD, PhD.
CareDx services will also be featured in 4 oral and 8 poster presentations in the main ATC programming.
Correlation of Donor-Derived Cell-Free DNA with Histology and Molecular Diagnoses of Kidney Transplant Biopsies. I. Moinuddin, Virginia Commonwealth University Medical Center
Donor Derived Cell Free DNA is Associated with De-Novo Donor Specific Antibody (DSA) Responses. S. Jordan, Cedars-Sinai Medical Center
Elevated Donor Derived Cell Free DNA (dd-cfDNA) Levels in the Presence of Donor Specific Antibodies (DSA) Are a Strong Predictor of Antibody Mediated Rejection (ABMR) in Pediatric Renal Transplant Recipients. D. Puliyanda, Cedars-Sinai Medical Center
The Use of dd-cfDNA as a Predictive Tool for Outcome Decreased Kidney Function. T. Alhamad, Washington University School of Medicine
Donor-Derived Cell-Free DNA (dd-cfDNA) Course after Rejection in Pediatric Kidney Transplant Recipients. R. Swinford, University of Texas at Houston
Donor-Derived Cell-Free DNA for Surveillance in Simultaneous Pancreas and Kidney Transplant Recipients, Can We Extrapolate from Kidney Transplant Alone? O. Olaitan, Rush University Medical Center
Donor Derived Cell Free DNA (dd-cfDNA) May Aid in the Diagnosis of BK Virus Nephropathy. D. Brennan, Johns Hopkins Hospital
External Validation of Donor-Derived Cell-Free DNA to Detect Rejection in Kidney Transplant Recipients. E. Huang, Cedars-Sinai Medical Center
Gene Expression Profiling for Cardiac Transplant Recipients: Results from the Outcomes AlloMap Registry. S. Hall, Baylor University Medical Center
Reference Ranges Donor-Derived Cell-Free DNA in a Heart Transplant Population. A. Kao, Saint Luke's Mid America Heart Institute
Subclinical Antibody Mediation Rejection in Stable Kidney Recipients with De Novo Donor Specific Antibodies and Correlation with Donor Derived Cell Free DNA Testing. A. Bregman, University of Colorado Hospital
Utility of AlloSure Monitoring in Simultaneous Kidney and Pancreas Recipients. J. Klein, University of Kansas Medical Center
"The number of quality presentations at ATC highlights our commitment to furthering innovation in transplantation," says Peter Maag, CEO at CareDx. "With our 20 years of experience in transplant care, we are supporting a number of multi-center clinical studies and adding a focus on investigator initiated trials. Personalized Medicine in transplantation is only in its beginning but will add significant value on long-term outcomes, as we optimize lifelong immunosuppressive therapy."
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients.
For more information, please visit: www.CareDx.com .
Forward Looking Statements
This press release includes forward-looking statements, including statements regarding the Company's participation at ATC. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including general economic and market factors, among others discussed in CareDx's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by CareDx with the SEC on March 6, 2019 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx's actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Chief Commercial Officer
Integrated Corporate Relations, Inc.
(C) Copyright 2019 GlobeNewswire, Inc. All rights reserved.